Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

被引：0
|
作者：
Jakubowiak, A. J. [1 ]
Hofmeister, C. [1 ]
Campagnaro, E. [2 ]
Kendall, T. [2 ]
Zimmerman, T. [3 ]
Schlossman, R. [4 ]
Reece, D. [5 ]
Lonial, S. [6 ]
Hari, M. [2 ]
Hector-Word, Z. [2 ]
Griffith, K. [2 ]
Tendler, C. [7 ]
Esseltine, D. L. [8 ]
Bock, T. [9 ]
Kaminski, M. [2 ]
Dollard, A. [10 ]
Kelley, S. [10 ]
Anderson, K. C. [4 ]
Richardson, P. G. [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Winship Canc Inst, Atlanta, GA USA
[7] Centocor Ortho Biotech LLC, Bridgewater, NJ USA
[8] Millennium Pharmaceut Takeda Oncol Co, Cambridge, MA USA
[9] Celgene Inc, Summit, NJ USA
[10] Multiple Myeloma Res Consortium, Norwalk, CT USA
来源：
CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S45 / S46
页数：2
相关论文
共 50 条
  • [1] Bortezomib and lenalidomide as front-line therapy for multiple myeloma
    Zou, Yandun
    Lin, Mingzhen
    Sheng, Zhixin
    Niu, Shaona
    [J]. LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2024 - 2031
  • [2] Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
    Manasanch, Elisabet E.
    Shah, Jatin J.
    Lee, Hans C.
    Weber, Donna M.
    Thomas, Sheeba K.
    Amini, Behrang
    Feng, Lei
    Berkova, Zuzana
    Hildebrandt, Michelle
    Orlowski, Robert Z.
    [J]. LANCET HAEMATOLOGY, 2018, 5 (12): : E628 - E640
  • [3] Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
    Oriol, Albert
    Canelo-Vilaseca, Marta
    Sanchez, Carla
    Abril, Laura
    Escoda, Lourdes
    Ibarra, Gladys
    Abella, Eugenia
    Motllo, Cristina
    Gonzalez-Montes, Yolanda
    Granada, Isabel
    Cabezudo, Elena
    Senin, Alicia
    Ben, Randa
    Jurado, Rebeca
    de Jaureguizar, Alejandro
    Ribera, Josep-Maria
    Sarra, Josep
    Sancho, Juan-Manuel
    Sureda, Anna
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S146 - S147
  • [4] Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
    Kaufman, Jonathan L.
    Shah, Jatin J.
    Laubach, Jacob P.
    Mitchell, Alaina R.
    Sharp, Cathy
    Lewis, Colleen
    Harvey, R. Donald
    Gleason, Charise
    Casbourne, Daniela
    Nooka, Ajay K.
    Heffner, Leonard T.
    Richardson, Paul G.
    Orlowski, Robert Z.
    Lonial, Sagar
    [J]. BLOOD, 2012, 120 (21)
  • [5] Bortezomib in the front-line treatment of multiple myeloma
    Richardson, Paul G.
    Mitsiades, Constantine
    Schlossman, Robert
    Ghobrial, Irene
    Hideshima, Teru
    Munshi, Nikhil
    Anderson, Kenneth C.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1053 - 1072
  • [6] Phase II Trials Evaluating Bortezomib/Lenalidomide/Dexamethasone in Multiple Myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 198 - 199
  • [7] Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome
    Roussel, Murielle
    Lauwers-Cances, Valerie
    Robillard, Nelly
    Hulin, Cyrille
    Leleu, Xavier
    Benboubker, Lotfi
    Marit, Gerald
    Moreau, Philippe
    Pegourie, Brigitte
    Caillot, Denis
    Fruchart, Christophe
    Stoppa, Anne-Marie
    Gentil, Catherine
    Wuilleme, Soraya
    Huynh, Anne
    Hebraud, Benjamin
    Corre, Jill
    Chretien, Marie-Lorraine
    Facon, Thierry
    Avet-Loiseau, Herve
    Attal, Michel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2712 - +
  • [8] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    [J]. International Journal of Hematology, 2020, 111 : 673 - 680
  • [9] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [10] Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
    Hansen, Doris K.
    Gautam, Santosh
    Lafeuille, Marie-Helene
    Rossi, Carmine
    Moore, Bronwyn
    Tardif-Samson, Anabelle
    Thompson-Leduc, Philippe
    Fu, Alex Z.
    Cortoos, Annelore
    Kaila, Shuchita
    Fonseca, Rafael
    [J]. BLOOD, 2023, 142
12345